EIN Presswire is celebrating 30 years! Follow us on Substack for customer insights, interviews, and more!

EIN Presswire is celebrating 30 years! Follow us on Substack for customer insights, interviews, and more!

World Media Directory · RSS · Email Newsletters

There were 228 press releases posted in the last 24 hours and 429,269 in the last 365 days.

Press Releases on November 12, 2024

2,033 Press Releases

Published on November 12, 2024 - 21:05 GMT

QIAGEN collaborates with McGill University to advance microbiome research

Montreal, Canada, and Venlo, the Netherlands, Nov. 12, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a collaboration with the McGill University Centre for Microbiome Research to support microbiome research …

Distribution channels: Media, Advertising & PR, Technology ...
Published on November 12, 2024 - 21:05 GMT

ICU Medical Announces Third Quarter 2024 Results and Updates Its Fiscal Year 2024 Guidance

SAN CLEMENTE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended September 30, 2024. …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...
Published on November 12, 2024 - 21:05 GMT

Eloxx Pharmaceuticals Announces Key Corporate Accomplishments

Data from Eloxx’s proof-of-concept trial in patients with nonsense mutation Alport Syndrome (NMAS) presented in late-breaking presentation at American Society of Nephrology (ASN) Kidney Week New protein analyses confirm production of both collagen alpha 4 …

Distribution channels: Healthcare & Pharmaceuticals Industry, Technology ...
Published on November 12, 2024 - 21:05 GMT

QIAGEN und McGill University starten Partnerschaft zur Förderung der Mikrobiomforschung

QIAGEN und die McGill University initiieren gemeinsame Projekte im Bereich der Mikrobiomforschung, um evidenzbasiertes Wissen für die Medizin und die öffentliche Gesundheit zu generieren //McGill dient als Beta-Teststelle für neue Mikrobiom- …

Distribution channels: Companies, Technology ...
Published on November 12, 2024 - 21:05 GMT

Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Announced Exclusive Licensing Agreement with Viatris for Sotagliflozin in all Markets Outside of the U.S. and Europe Completed ZYNQUISTA™ FDA Advisory Committee Meeting; PDUFA Goal Date December 20, 2024 Concluded Enrollment Screening For Phase 2b PROGRESS …

Distribution channels:
Published on November 12, 2024 - 21:05 GMT

Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Robust and expanding development portfolio with multiple key data readouts projected over the next 18 months Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. ( …

Distribution channels:
Published on November 12, 2024 - 21:05 GMT

Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Appointed Douglas Williams, Ph.D. as Chair of the Board of Directors FDA Clearance of Investigational New Drug Application (IND) for systemic lupus erythematosus (SLE) Expanded Management Team with the Appointment of Gary Hao, Ph.D. as Vice President of …

Distribution channels:
Published on November 12, 2024 - 21:05 GMT

ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the third quarter ended …

Distribution channels: ...
Published on November 12, 2024 - 21:05 GMT

Apyx Medical Corporation to Attend 15th Annual Craig-Hallum Alpha Select Conference

CLEARWATER, Fla., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today …

Distribution channels:
Published on November 12, 2024 - 21:05 GMT

iBio Reports Fiscal First Quarter 2025 Financial Results

SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) today reported financial results for the fiscal first quarter ended September 30, 2024 and provided a corporate update on its progress. “In our fiscal first quarter we advanced our …

Distribution channels: Business & Economy, Technology ...
Published on November 12, 2024 - 21:05 GMT

EverCommerce Announces Josh McCarter as the Leader of Its EverPro Vertical

DENVER, Nov. 12, 2024 (GLOBE NEWSWIRE) -- EverCommerce Inc. (NASDAQ: EVCM), a leading provider of SaaS solutions for service SMBs, announced today the hiring of Josh McCarter as the leader of its EverPro home and field services vertical, reporting to …

Distribution channels: IT Industry ...
Published on November 12, 2024 - 21:05 GMT

Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Submission of New Drug Application for Paltusotine for the Treatment of Acromegaly Completed Upsized Public Offering of $575M of Common Stock Debut of First Drug Candidate from a Novel Nonpeptide Drug Conjugate Platform at North American Neuroendocrine …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...
Published on November 12, 2024 - 21:05 GMT

Oportun Completes Sale of its Credit Card Portfolio

SAN CARLOS, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Oportun (Nasdaq: OPRT), a mission-driven financial services company, today announced that it has closed the previously agreed upon sale of its credit card portfolio to Continental Finance. Completing …

Distribution channels: Banking, Finance & Investment Industry, Media, Advertising & PR ...
Published on November 12, 2024 - 21:05 GMT

Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025

Transplant centers representing about 9% of German transplant volumes and about 2% of U.S. transplant volumes have signed on to use GraftAssure kitted research test in early launch phase FDA pre-submission process for approval of kitted clinical test is …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...
Published on November 12, 2024 - 21:05 GMT

HF Foods Reports Third Quarter 2024 Financial Results

Increase in Net Revenue as Company Continues to Execute Operational Transformation Plan Pre-Recorded Earnings Call Webcast Available on Investor Relations Website LAS VEGAS, Nov. 12, 2024 (GLOBE NEWSWIRE) -- HF Foods Group Inc. (NASDAQ: HFFG) (“HF Foods” …

Distribution channels:
Published on November 12, 2024 - 21:05 GMT

Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business Update

Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ in rare pediatric disease HLHS has achieved more than 80% enrollment Positive Type C meeting with U.S. FDA confirmed ELPIS II is pivotal and, if positive, acceptable for Biological License …

Distribution channels:
Published on November 12, 2024 - 21:05 GMT

Hallador Energy Company Reports Third Quarter 2024 Financial and Operating Results

- Signs Non-Binding Term Sheet with Leading Global Data Center Developer to Supply Power for 10+ years - - Q3 Total Revenue of $105.0 Million - - Q3 Net Income of $1.6 Million or $0.04 Earnings per Share - - Q3 Operating Cash Flow of ($12.9) Million - - Q3 …

Distribution channels: Business & Economy ...
Published on November 12, 2024 - 21:05 GMT

Hyperfine, Inc. Reports Third Quarter 2024 Financial Results

GUILFORD, Connecticut, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the …

Distribution channels:
Published on November 12, 2024 - 21:05 GMT

FibroGen Reports Third Quarter 2024 Financial Results

Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) …

Distribution channels: Business & Economy, Technology ...
Published on November 12, 2024 - 21:05 GMT

VirTra Reports Third Quarter and Nine Month 2024 Financial Results

Q3 Bookings Grow 51% Quarter-Over-Quarter to $8.9 Million, Bringing YTD Total to $17.7 Million Gross Margin Expands to 73% CHANDLER, Ariz., Nov. 12, 2024 (GLOBE NEWSWIRE) -- VirTra, Inc. (Nasdaq: VTSI) (“VirTra” or the “Company”), a global provider of …

Distribution channels:

Previous 11 12 13 14 15 16 17 18 19 20 21 Next

Previous Day 2024 Calendar Next Day